Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| No NIH funding | Other Identifier | 11.15.23 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Monash University | OTHER |
Not provided
Not provided
Not provided
Not provided
The International Post-Stroke Epilepsy Research Repository (IPSERR): The study aims to collate and categorize data reported by post-stroke epilepsy (PSE) researchers and lodge it within the IPSERR. Using the IPSERR database, we will conduct two individual patient data (IPD) analyses: (1) determine epilepsy, functional, and cognitive outcomes in stroke patients who develop post-stroke seizure and (2) build and validate post-stroke epilepsy prediction model and compare performance against existing models.
The cerebrovascular disease is the most common cause of late-onset epilepsy. PSE is associated with increased morbidity, including cognitive decline, dependence, and poor quality of life, and is a critical determinant factor of stroke prognosis. We recently reported a systematic review and meta-analysis of 71 papers that suggested that post-stroke seizures are associated with more significant mortality and poor functional and cognitive outcomes (PMID:37721736). In this study, we observed disparate methods used by the individual investigators. We also noted variations in study reporting. PI aims to analyze existing individual patient data, including those analyzed in the systematic review, by collaborating with colleagues in the field and developing IPSERR into a resource for future collaborative studies that will tackle anti-epileptogenesis drug trial design.
Design and Rationale:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Post-stroke epilepsy | Stroke patients aged ≥18 years, with ischemic or hemorrhagic stroke, presenting with early or late onset post-stroke seizures. |
| |
| No post-stroke epilepsy | Stroke patients aged ≥18 years, with ischemic or hemorrhagic stroke, presenting with no post-stroke seizures. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Presence of stroke, either ischemic or hemorrhagic (intracerebral and subarachnoid) | Other | Presence of ischemic or hemorrhagic stroke confirmed by neuroimaging and clinical diagnosis |
| Measure | Description | Time Frame |
|---|---|---|
| Mortality (modified Rankin Scale = 6) | The modified Rankin Scale (mRS) is a clinician-reported measure of global disability for evaluating recovery from stroke. It ranges from 0 (no symptoms) to 6 (death). | At 1 year, 2 year, and 5 year follow-up |
| Poor functional outcome (modified Rankin Scale 3-6) | The modified Rankin Scale (mRS) is a clinician-reported measure of global disability for evaluating recovery from stroke. It ranges from 0 (no symptoms) to 6 (death), with 0-2 indicating a good functional outcome and 3-6 indicating a poor functional outcome. | At 1 year, 2 year, and 5 year follow-up |
| Seizure frequency | Number of seizures post-stroke identified clinically or based on an electroencephalogram (EEG). | At 1 year, 2 year, and 5 year follow-up |
| Seizure severity | Defined by impaired awareness and the presence of bilateral tonic or clonic seizures. | At 1 year, 2 year, and 5 year follow-up |
| Occurrence or frequency of status epilepticus | Status epilepticus is defined as a seizure or series of seizures lasting more than 30 minutes without recovery of consciousness based on electroencephalogram (EEG) findings. | At 1 year, 2 year, and 5 year follow-up |
| Length of hospital stay | The duration of hospital admission for a stroke is measured in days. | At 1 year, 2 year, and 5 year follow-up |
| Cognitive decline assessed on an 11-question Mini-Mental State Examination (MMSE) tool or a 30-point Montreal Cognitive Assessment (MoCA) scale |
| Measure | Description | Time Frame |
|---|---|---|
| Recurrent stroke | A diagnosis of a subsequent stroke will be made based on neuroimaging. | At 1 year, 2 year, and 5 year follow-up |
| Antiseizure medication discontinuation | Switching of antiseizure medication (ASM) defined as discontinuation of one ASM and starting of another due to adverse events or treatment ineffectiveness. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with stroke aged ≥18 years, with ischemic or hemorrhagic stroke, presenting with early or late post-stroke seizures. Patients presenting ≤1 week will be classified as early seizures and >1 week will be classified as late seizures.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nishant K Mishra, MD PhD | Yale University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Yale University | New Haven | Connecticut | 06511 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37968000 | Background | Mishra NK, Kwan P, Tanaka T, Sunnerhagen KS, Dawson J, Zhao Y, Misra S, Wang S, Sharma VK, Mazumder R, Funaro MC, Ihara M, Nicolo JP, Liebeskind DS, Yasuda CL, Cendes F, Quinn TJ, Ge Z, Scalzo F, Zelano J, Kasner SE; International Post-Stroke Epilepsy Research Consortium (IPSERC); International Post Stroke Epilepsy Research Consortium (IPSERC). Clinical characteristics and outcomes of patients with post-stroke epilepsy: protocol for an individual patient data meta-analysis from the International Post-stroke Epilepsy Research Repository (IPSERR). BMJ Open. 2023 Nov 15;13(11):e078684. doi: 10.1136/bmjopen-2023-078684. |
Not provided
Not provided
The PI (NKM) will create a centralized database, collect, and analyze PSE patient data, and establish common data protocols. IPSERR welcomes all PSE researchers as impartial members, granting membership to institutions. Each organization will have a role in the IPSERR steering committee. One named individual, usually the principal investigator of the contributing study, will represent the institution in the IPSERR. Steering committee members will review and approve research proposals. To address data concerns like confidentiality, reliability, and authorship, strict guidelines will be set for handling patient data, promoting ethical data sharing and collaborators' involvement in publications. Data will be securely stored, and access will be restricted to authorized individuals. The IPSERR constitution will define eligibility, data protection, storage, compatibility, and documentation.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D020521 | Stroke |
| D004827 | Epilepsy |
| ID | Term |
|---|---|
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
MMSE is tests cognitive function. It is scored out of 30, with a score of ≤26 indicating cognitive impairment. MoCA assesses mild cognitive dysfunction. It is scored out of 30, with a score of ≤24 indicating cognitive impairment. |
| At 1 year, 2 year, and 5 year follow-up |
| At 1 year, 2 year, and 5 year follow-up |
| Treatment adverse events | Adverse events are defined as any side effects occurring due to antiseizure medication administration during the course of the study. | At 1 year, 2 year, and 5 year follow-up |
| Depression assessed on 21-item Hamilton Depression Rating Scale (HAM-D) | HAM-D is a tool used to assess depression symptoms. Depression post-ASM administration is defined as HAM-D score of 0-13 mild; 14-17 mild to moderate; >17 moderate to severe depression. | At 1 year, 2 year, and 5 year follow-up |
| Anxiety assessed on 14-item Hamilton Anxiety Rating Scale (HAM-A) | HAM-A is a psychological questionnaire that measures the severity of a patient's anxiety. Anxiety post-ASM administration is defined as HAM-A score of <17 mild; 18-24 moderate; 25-30 moderate to severe anxiety. | At 1 year, 2 year, and 5 year follow-up |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |